Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Multicenter Trial of ECMO in Children with Severe Cardiac Failure using the Cardiohelp System

Award Number: R01FD007833
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2023
PERIOD OF PERFORMANCE END DATE: 07/31/2029

Group Awards By:

View Award Description

Multicenter Trial of ECMO in Children with Severe Cardiac Failure using the Cardiohelp System - PROJECT SUMMARY/ABSTRACT While ECMO is widely considered the standard-of-care for children with severe cardiac failure requiring emergent life support, no ECMO circuit has ever been FDA-approved or cleared for children. The primary reason is that pediatric clinicians have long had unfettered access to all the equipment needed to assemble an ECMO circuit without performing an FDA-approval trial by using equipment off-label that has been FDA-cleared for cardiopulmonary bypass. Nevertheless, studies suggest the Cardiohelp system can support children with cardiopulmonary failure for days or weeks with manageable complications. This resubmission responds to a favorable review of the “Multicenter Trial of ECMO for Children with Severe Cardiac Failure using the Cardiohelp System”, to evaluate safety and effectiveness of the System to provide up to 30d of circulatory support to children with severe cardiac failure where other options have failed, and clinical worsening is expected, in order to support FDA clearance of the system in children. The study will be conducted at 5 centers with extensive experience and favorable outcomes using the Cardiohelp system in children. The target N is 50 children aged 0 to 16 years (3 to 80 kg) receiving VA ECMO. The primary goal is to generate the data needed to secure FDA-clearance of the first complete ECMO circuit in children with cardiac failure, and to determine whether complications, i.e., hemolysis, circuit thrombosis/stroke, and renal failure are acceptable in children ≤ 10 kg compared to those > 10 kg. The trial IDE (G220250) has Approval from the FDA (Appendix B). Specific aims are: SPECIFIC AIM 1 (Effectiveness): To determine whether ≥30 of 50 children (≥60%) supported with the Cardiohelp system for severe cardiac failure survive to recovery, durable VAD implant, transplant, or 30 days of support in the absence of severe neurological injury due to stroke as defined by the PSOM score. SPECIFIC AIM 2 (Safety): To determine whether children supported with the Cardiohelp system for severe cardiac failure experience key severe adverse outcomes (symptomatic stroke; severe hemolysis; thromboembolism or major device malfunction leading to circuit change; renal failure) within pre- specified Performance Goals (PGs): SPECIFIC AIM 3 (Regulatory): To generate the data necessary to allow the Cardiohelp to serve as a predicate device (if worthy) to support FDA clearance of future ECMO systems under the 510(k) pathway. SPECIFIC AIM 4 (Regulatory): To harmonize SAE definitions across different forms of MCS to enable device comparisons irrespective of the presence of an oxygenator, as the line between VAD and ECMO is blurring. Trial infrastructure includes a CCC at Stanford University (IDE sponsor) and a DCC at Boston Children's Hospital. The trial will be led by Drs. Sleeper, Almond and Ozment, with complementary expertise (Statistical; Regulatory; ECMO & Critical Care) and a history of successful collaboration in trial execution.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $613,338 )
2026	2026	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Food and Drug Administration Research	001	1	6/16/2026	SUPPLEMENT FOR EXPANSION	$613,338
2026	2023	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Food and Drug Administration Research	000	1	6/8/2026	NEW	$0
														Subtotal = $613,338

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Food and Drug Administration Research	000	1	7/21/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Food and Drug Administration Research	000	1	7/13/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $608,916 )
2023	2023	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Food and Drug Administration Research	000	1	9/20/2023	NEW	$608,916
2023	2023	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Food and Drug Administration Research	001	1	9/20/2023	NEW	$0
														Subtotal = $608,916

Grand Total All Awards = $1,222,254

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Multicenter Trial of ECMO in Children with Severe Cardiac Failure using the Cardiohelp System

Award Number: R01FD007833

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2023

PERIOD OF PERFORMANCE END DATE: 07/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer